Role for Afatinib in p16-Negative Head and Neck Cancer?

Video

This video reviews results of LUX-Head & Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.

In this video, Barbara Burtness, MD, of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut, discusses results of LUX-Head & Neck 2, a randomized, placebo-controlled, phase III trial that tested afatinib as adjuvant therapy after chemoradiation in patients with unresected high/intermediate-risk, squamous cell head and neck cancer.

The trial was halted for futility last year when an independent panel determined afatinib was unlikely to provide benefit in this group of patients, though subgroup analyses suggest that some may derive benefit.

Results of the study (abstract 6001) were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.